2003
DOI: 10.1016/s0048-7333(02)00020-3
|View full text |Cite
|
Sign up to set email alerts
|

Does co-location matter for formal knowledge collaboration in the Swedish biotechnology–pharmaceutical sector?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
90
0
2

Year Published

2008
2008
2023
2023

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 168 publications
(95 citation statements)
references
References 24 publications
3
90
0
2
Order By: Relevance
“…Geographically proximate firms are able to leverage information exchanged informally through local trade shows, conferences, seminars, communication with personnel from nearby research institutes, organized social activities, or from employees switching companies (Aldieri and Cincera, 2009, Lemarié et al, 2001, McKelvey et al, 2003and Saxenian, 1990. Much of the information or knowledge being exchanged is tacit in nature (Audretsch, 1998).…”
Section: Informal Network Relationshipsmentioning
confidence: 99%
See 1 more Smart Citation
“…Geographically proximate firms are able to leverage information exchanged informally through local trade shows, conferences, seminars, communication with personnel from nearby research institutes, organized social activities, or from employees switching companies (Aldieri and Cincera, 2009, Lemarié et al, 2001, McKelvey et al, 2003and Saxenian, 1990. Much of the information or knowledge being exchanged is tacit in nature (Audretsch, 1998).…”
Section: Informal Network Relationshipsmentioning
confidence: 99%
“…For instance, there has been a stream of research questioning the value of co-location or geographically proximate firms for firms' external learning. There has been research reporting no effect of geographic proximity on firm innovation (e.g., Ganesan et al, 2005 andTallman andPhene, 2007); there have also been studies suggesting that, although geographically proximate firms might be a useful group to turn to for knowledge acquisition, such value is not always fundamental and depends on contextual (e.g., Davenport, 2005, Lemarié et al, 2001and McKelvey et al, 2003 and firm (e.g., Folta, 2009 andWhittington et al, 2009) factors. We argue that one critical situational factor is the venture's international exposure from alliance partners.…”
mentioning
confidence: 99%
“…In this sector, new technological opportunities often emerge from small high-tech biotechnology firms, companies tend to engage in a wide array of relationships in order to build a 'radar-function' on new technologies. Therefore, given the technological challenges, opportunities and costs of bringing new products to the market, companies in these sectors are extensively involved in strategic alliances with a variety of external partners (Hall and Bagchi-Sen 2002;McKelvey, Alm, and Riccaboni 2003). In particular, large pharmaceutical firms are building a large portfolio of relationships.…”
Section: Samplementioning
confidence: 99%
“…Previous studies have highlighted the importance and characteristic of strategic alliances in a context characterized by technological changes and emerging new technologies (Grant and Baden-Fuller, 2004). In effect, early-stage biotechnology companies secure backward vertical alliances with academia to get access to basic knowledge and state-of-the-art technologies and forward vertical alliances with large pharmaceutical companies to access to complementary assets, expertise and financial resources (Galambos and Sturchio, 1998;McKelvey et al, 2003). As such, competencies and expertise in key technologies have been rapidly developed in biotechnology companies through cooperative alliances.…”
Section: Strategic Alliancesmentioning
confidence: 99%